Loading
Every dated change on the records linked to Diffuse large B-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
R-CHOP × 6 (or Pola-R-CHP); consider 4 cycles plus 2 rituximab in young low-risk patients (FLYER). (NCCN Category 1)
Pola-R-CHP × 6 (POLARIX) or R-CHOP × 6; tafasitamab + lenalidomide + R-CHOP (frontMIND) pending approval for IPI 3-5; DA-EPOCH-R for double-hit lymphoma; CNS prophylaxis for high CNS-IPI (contested). (NCCN Pola-R-CHP category 1 for IPI 2-5)
CD19 CAR-T (axi-cel or liso-cel) preferred over salvage chemotherapy and transplant (ZUMA-7, TRANSFORM); bridging therapy while manufacturing; bispecific ± chemotherapy if CAR-T unavailable. (NCCN Category 1 (axi-cel, liso-cel))
R-CHOP × 4 with PET-guided omission of radiation (FLYER, S1001): 4 cycles if interim PET negative; involved-site radiotherapy if PET positive. (NCCN Category 1 (R-CHOP × 4 PET-adapted for stage I-II))
PFS HR 0.
Median overall survival 19.
A milestone in how this cancer is treated.
R/R follicular lymphoma after ≥2 lines (accelerated)
R/R follicular lymphoma with lenalidomide and rituximab
Median overall survival 13.
PFS HR 0.
PFS improved (HR reported 2025).
ORR 73% (37 of 51) in relapsed or refractory B-cell malignancies; two treatment-related deaths.
A milestone in how this cancer is treated.
Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)
R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)
In the follicular lymphoma cohort, objective response 80.
Overall survival hazard ratio 0.
A milestone in how this cancer is treated.
EU brand Tepkinly
Relapsed/refractory DLBCL or high-grade B-cell lymphoma after ≥2 lines (accelerated)
Relapsed/refractory DLBCL after ≥2 lines (accelerated)
Untreated DLBCL, IPI ≥2, with R-CHP (Pola-R-CHP)
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 3.7 years later, when the FDA's table was read.
Conditional marketing authorisation
R/R DLBCL ≥2 lines (conditional)
R/R follicular lymphoma after ≥2 lines (accelerated)
ORR 63%, CR 39%.
EFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Relapsed/refractory DLBCL after ≥2 systemic therapies
EU brand Minjuvi
EFS HR 1.
ORR 48%, CR 24%.
2-year PFS 76.
ORR 75.
EFS HR 0.
A milestone in how this cancer is treated.
Relapsed/refractory DLBCL; myeloma with bortezomib after ≥1 line
R/R DLBCL with lenalidomide, transplant-ineligible (accelerated)
3-year EFS 93.
ORR 60%, CR 43%.
Objective response in 73 per cent and complete response in 53 per cent of 256 evaluable patients, with grade 3 or worse cytokine release syndrome in 2 per cent.
A milestone in how this cancer is treated.
Relapsed/refractory DLBCL with bendamustine-rituximab after ≥2 lines (accelerated)
No difference in progression-free survival (hazard ratio 0.
Three-year progression-free survival 96 per cent with four cycles of R-CHOP plus two extra rituximab doses, non-inferior to six cycles, with roughly a quarter fewer adverse events.
A pivotal single-arm study supporting the approval of tisagenlecleucel in relapsed or refractory large B-cell lymphoma after two or more lines.
Objective response rate 45%, complete response 13%, in 53 patients with relapsed or refractory disease; FDA accelerated approval June 2018.
A milestone in how this cancer is treated.
Progression-free survival hazard ratio 0.
Progression-free survival hazard ratio 0.
High objective and complete response rates in refractory large B-cell lymphoma with durable remissions in a large minority; approved in October 2017.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.